Ebola Clinical Trial to Begin Amid Outbreak in DRC

The study will examine the efficacy of four drugs—an antiviral and three monoclonal antibodies—that are already being used to treat patients in Democratic Republic of Congo.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: Illustration of Ebola virus
© ISTOCK.COM, NOPPARIT

Health officials in Democratic Republic of Congo are planning to launch a clinical trial of four Ebola treatments, STAT reports. The experimental drugs include an antiviral medicine and three monoclonal antibodies.

Rather than have a control arm, the trial will compare the efficacy of the four experimental treatments against each other, at least in Democratic Republic of Congo (DRC). Other countries that participate in the trial may choose to include a current treatment as a control arm. The drugs include the antiviral Remdesivir, and the antibodies ZMapp, REGN 3470-3471-3479, and mAB 114, which is being developed by DRC’s National Institute of Biomedical Research and the US National Institutes of Health.

The study will likely run over the course of several outbreaks in multiple countries, and it will probably begin this month, Jeremy Farrar, the head of the Wellcome Trust who is the co-chair ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Conceptual 3D image of DNA on a blue background.

Understanding the Nuts and Bolts of qPCR Assay Controls 

Bio-Rad
Takara Bio

Takara Bio USA Holdings, Inc. announces the acquisition of Curio Bioscience, adding spatial biology to its broad portfolio of single-cell omics solutions

Sapio Sciences

Sapio Sciences Announces Enhanced Capabilities for Chemistry, Immunogenicity, GMP and Molecular Biology

Biotium Logo

Biotium Unveils the Most Sensitive Stains for DNA or RNA with New EMBER™ Ultra Agarose Gel Kits